Rome, Italy
NCT Number: NCT00486473
Multihance Versus Magnevist in Breast MRI
To show if one MRI contrast agent is better than another one in the diagnosis of malignant breast lesions compared to histopathology
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 3
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Provides written informed consent
- Female
- Age 18 years or older
- Suspicious or known breast lesion based on results from mammography or ultrasound
- Planned to undergo histological diagnosis of breast lesion by having a non surgical biopsy or breast surgery within 30 days after the MRI exam
Exclusion criteria
- Body weight > 100 kg
- Pregnant or lactating
- Server or end-stage organ failure
- Moderate to severe renal impairment
- Undergoing radiotherapy or completed radiotherapy in the last 18 months
- Chemotherapy within 6 months of the 1st MRI exam
Treatment and study plan
Multihance
Drug0.5 Molar at a single dose injection
Magnevist
Drug0.5M at a single dose injection
Primary outcomes
-
Sensitivity in diagnosing breast lesions compared to histopathology results
Time frame: up to 6 months
Secondary outcomes
-
Sensitivity, specificity, accuracy, PPV and NPV at region, breast and patient levels
Time frame: up to 6 months
Sponsors and collaborators
Lead sponsor
Bracco Diagnostics, Inc
Industry
Registry information
Official study title
Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast
Acronym: DETECT
Important dates
- Study start
- 2007
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Jun 14, 2007
- Registry last updated
- Jul 15, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472
Adnexal Diseases, Breast Cancer
Bethesda, Maryland, United States
View Trial DetailsRisk Communication Within Mexican-American Families
NCT00469339
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsBreast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
NCT00006421
Breast Cancer, Breast Diseases
Bethesda, Maryland, United States
View Trial DetailsEndocrine Response in Women With Invasive Lobular Breast Cancer
NCT02206984
Breast Cancer, Breast Diseases
Birmingham, Alabama, United States
View Trial Details